This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Opinion: Discussing the results from the Phase 2b Study evaluating Takeda's TAK-279 for the treatment of active psoriatic arthritis

Ticker(s): TAK

Who's the expert?

Institution: Arthritis and Rheumatism Assoc.

  • Board certified rheumatologist in single specialty practice
  • treats over 1000 patients with PsA

Interview Goal
This interview will focus on the results from the Phase 2b Study evaluating Takeda's TAK-279 for the treatment of active psoriatic arthritis

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.